Magnesium vitamin B6

Phase 2

MMclean Hospital

Magnesium vitamin B6 is one of 50 therapeutic programs targeting Bipolar I Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bipolar I DisorderRecruiting

Bipolar I DisorderPhase 2

Recruiting

Competition

Competitive Landscape

57 competitors in Bipolar I Disorder

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

12 2

Risperdal

WWim Janssens

Approved

4 3

Lexapro

Geodon

7 5

Vraylar

AbbVie

Phase 3

4 6

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—7

Lithobid

SSolvay Pharmaceuticals

Rozerem

3 9

Tegretol

Novartis

Phase 3

3 10

Depakote

Teva

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Bipolar I Disorder

NCT05837104

Clinical

Trials by Indication[1]

Bipolar I Disorder1 trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Magnesium Vitamin B6 in Combination With Treatment as Usual in First Episode of Bipolar I Disorder

Recruiting·MMclean Hospital·Phase 2·NCT05837104·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Magnesium vitamin B6. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Magnesium vitamin B6. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mclean Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMclean Hospital

Magnesium vitamin B6

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Bipolar I Disorder1 trial

References

Drug Info

Quick Facts

Related News